examined the effect of Tirzepatide added to insulin treatment in individuals with class II obesity and found that the dual agonist was able to improve glucose control (HbA1c −0.59%) and induce relevant weight loss (−10% of baseline body weight) after 8 months of treatment [65]. Here, INS is linked to obesity due to melanocortin 4 receptor deficiency.